[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C@H1][/C][=C][/C@@H1][Branch2][Ring2][N][C@][Branch2][Ring2][Ring2][C][C][C@H1][Branch2][Ring1][=N][C][C][=Branch1][C][=O][O][C@@H1][Ring1][=N][/C][=Branch1][S][=C][/C][=C][/C@@H1][Branch1][C][C][C][=C][C][=C][C][=N][Ring1][=Branch1][/C][O][Branch1][C][C][O][O][C][=Branch1][C][=O][N][C][C][N][Branch1][Branch1][C][C][Ring1][=Branch1][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable inhibitor of the splicing factor 3B subunit 1 (SF3B1), with potential antineoplastic activity. Upon administration, H3B-8800 binds to and blocks the activity of SF3B1, a core spliceosome protein that is mutated in various cancer cells. This modulates RNA splicing by preventing aberrant mRNA splicing by the spliceosome, blocks RNA mis-splicing, enhances proper RNA splicing and prevents the expression of certain tumor-associated genes. This leads to an induction of apoptosis and prevents tumor cell proliferation. In many cancer cells, core spliceosome proteins, including SF3B1, U2 small nuclear ribonucleoprotein auxiliary factor 1 (U2AF1), serine/arginine-rich splicing factor 2 (SRSF2) and U2 small nuclear ribonucleoprotein auxiliary factor subunit-related protein 2 (ZRSR2), are mutated and aberrantly activated leading to a dysregulation of mRNA splicing."}]